Compare HCA Health Inc (HCA) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HCA Health Inc vs Medpace Holdings Inc — how do they compare? HCA Health Inc trades at $442.02 (market cap $96.35B), while Medpace Holdings Inc trades at $605 (market cap $16.82B). The key difference: HCA Health Inc is far larger — about 5.7× Medpace Holdings Inc's market cap, and HCA Health Inc pays a 0.7% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold HCA Health Inc for 76 Days and Medpace Holdings Inc for 14 Days on average.
| HCA | MEDP | |
|---|---|---|
Market Cap | $96.35B | $16.82B |
Volume | 1,079,453 | 223,093 |
Sector | Health | Health |
52-Week High | $545.13 | $630.19 |
52-Week Low | $361.32 | $393.42 |
Typical Hold Time | 76 Days | 14 Days |
Enterprise Value | $146.88B | $16.44B |
Dividend Yield | 0.7% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HCA Healthcare (HCA) trades at $439.17, up 1.61% on the day, with a bullish technical signal and strong fundamentals. The stock shows consistent revenue growth, reaching $75.6B in 2025, and has beaten EPS estimates for three consecutive quarters. Analyst consensus is bullish with a $461.12 price target, supported by solid cash flow from operations of $12.64B and a net income margin of 8.77%.
The outlook remains positive given earnings momentum and operational efficiency, but risks include ongoing legal investigations and high debt levels. Upside potential exists if the company maintains its earnings beat streak and manages payer-mix challenges effectively.
MEDP trades at $604.25, up 0.22% today, with a neutral technical signal and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected on October 21, 2026. Revenue grew to $2.53 billion in 2025, with a net income margin of 17.67% and robust ROE of 162.15%. Analyst consensus is a $620.44 price target, though institutional sentiment is mixed with recent CEO share sales.
Outlook remains positive given earnings momentum and projected 2026 revenue growth to $2.8 billion. Key risks include high valuation multiples and insider selling. The stock offers upside to consensus target but requires monitoring of Q3 earnings and competitive pressures in medical services.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About HCA Health Inc
HCA Healthcare is a Nashville-based healthcare provider organization operating the largest collection of acute-care hospitals in the U.S. As of December 2021, the firm owned and operated 182 hospitals, 125 freestanding outpatient surgery centers, and a broad network of physician offices, urgent care clinics, and freestanding emergency rooms across nearly 20 states and a small foothold in England.
Read more on HCA →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
